CytomX Therapeutics, Inc. (CTMX) Bundle
Understanding CytomX Therapeutics, Inc. (CTMX) Revenue Streams
Understanding CytomX Therapeutics, Inc.’s Revenue Streams
The total revenue for the three months ended September 30, 2024, was $33,432 thousand, compared to $26,384 thousand for the same period in 2023, reflecting an increase of $7,048 thousand or approximately 26.7%. For the nine months ended September 30, 2024, total revenue was $100,010 thousand, up from $74,607 thousand in 2023, indicating a year-over-year growth of $25,403 thousand or about 34.1%.
Breakdown of Primary Revenue Sources
The following table summarizes revenue by collaboration partner for the specified periods:
| Collaboration Partner | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Nine Months Ended September 30, 2024 (in thousands) | Nine Months Ended September 30, 2023 (in thousands) |
|---|---|---|---|---|
| AbbVie | $0 | $0 | $0 | $3,988 |
| Amgen | ($783) | $1,627 | $1,491 | $5,124 |
| Astellas | $2,553 | $4,630 | $23,497 | $18,685 |
| Bristol Myers Squibb | $22,977 | $14,028 | $56,042 | $35,630 |
| Regeneron | $2,896 | $2,913 | $7,925 | $5,249 |
| Moderna | $5,789 | $3,186 | $11,055 | $5,931 |
| Total Revenue | $33,432 | $26,384 | $100,010 | $74,607 |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate reflects significant fluctuations across different agreements. The primary contributors to the revenue increase for the three months ended September 30, 2024, include:
- Bristol Myers Squibb Agreement: Increased revenue by $8,949 thousand due to higher completion percentages of existing research collaboration programs.
- Astellas Agreement: Increased revenue by $4,812 thousand driven by milestone payments.
- Moderna Agreement: Increased revenue by $5,124 thousand attributed to higher completion percentages.
In contrast, the decrease in revenue from the Amgen Agreement was attributed to cumulative adjustments resulting from increased projected hours to completion, which negatively impacted current period revenue.
Contribution of Different Business Segments to Overall Revenue
The contribution of various collaborations to overall revenue illustrates the diversified revenue streams, with Bristol Myers Squibb and Astellas being the largest contributors in recent periods.
| Business Segment | Contribution to Revenue (Nine Months Ended September 30, 2024 in thousands) |
|---|---|
| Bristol Myers Squibb | $56,042 |
| Astellas | $23,497 |
| Moderna | $11,055 |
| Regeneron | $7,925 |
| Amgen | $1,491 |
| AbbVie | $0 |
Analysis of Significant Changes in Revenue Streams
The revenue stream changes are significantly influenced by collaboration agreements. Notably:
- The termination of the AbbVie Agreement in March 2023 resulted in a complete cessation of revenue from this source.
- Milestone payments under the Astellas Agreement contributed a total of $10.0 million in 2024, enhancing revenue visibility.
- Revenue under the Amgen Agreement fluctuated due to adjustments in projected hours, impacting overall revenue negatively.
A Deep Dive into CytomX Therapeutics, Inc. (CTMX) Profitability
A Deep Dive into CytomX Therapeutics, Inc.'s Profitability
Gross Profit Margin: As of September 30, 2024, the gross profit margin was approximately 17.1%, compared to 8.2% for the same period in 2023.
Operating Profit Margin: The operating profit margin for the three months ended September 30, 2024, stood at 12.3%, an increase from 11.8% in the previous year.
Net Profit Margin: The net profit margin for the three months ended September 30, 2024, was 17.1%, up from 11.3% in the same quarter of 2023.
Trends in Profitability Over Time:
- For the nine months ended September 30, 2024, total revenue was $100.0 million, up from $74.6 million in 2023.
- Net income for the nine months ended September 30, 2024, was $12.99 million, compared to a net loss of $1.41 million in the same period of 2023.
Comparison of Profitability Ratios with Industry Averages:
| Metric | CytomX Therapeutics (2024) | Industry Average |
|---|---|---|
| Gross Profit Margin | 17.1% | 50% |
| Operating Profit Margin | 12.3% | 20% |
| Net Profit Margin | 17.1% | 15% |
Analysis of Operational Efficiency:
- Total operating expenses for the nine months ended September 30, 2024, were $92.69 million, compared to $80.49 million in 2023.
- Research and development expenses increased to $68.59 million in 2024 from $58.29 million in 2023.
- General and administrative expenses rose to $24.10 million from $22.19 million year-over-year.
Key Financial Metrics:
| Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Total Revenue | $33.43 million | $26.38 million |
| Net Income (Loss) | $5.74 million | $2.99 million |
| Operating Income (Loss) | $4.11 million | $3.12 million |
Debt vs. Equity: How CytomX Therapeutics, Inc. (CTMX) Finances Its Growth
Debt vs. Equity: How CytomX Therapeutics, Inc. Finances Its Growth
As of September 30, 2024, CytomX Therapeutics, Inc. reported total liabilities of $162.4 million, a decrease from $249.2 million as of December 31, 2023. This includes current liabilities of $119.2 million, which consist of accounts payable, accrued liabilities, and deferred revenue. The company has no long-term debt on its balance sheet, indicating a reliance on equity financing to fund its operations and growth initiatives.
Debt Levels
The company has no long-term debt, and its short-term liabilities primarily consist of deferred revenue, which was $96.1 million as of September 30, 2024. This reflects the company's strategy to finance its operations through equity rather than debt, which is common among biopharmaceutical companies that are in early stages of development.
Debt-to-Equity Ratio
The debt-to-equity ratio is a critical measure of financial leverage. CytomX's debt-to-equity ratio is effectively 0, given that it has no long-term debt. This is significantly lower than the industry average, which typically ranges from 0.5 to 1.0 for biotechnology firms, indicating a conservative approach to leveraging. The absence of debt reduces financial risk but may limit potential growth opportunities that could be financed through leverage.
Recent Debt Issuances and Credit Ratings
As of the latest reports, CytomX has not issued any debt instruments, nor does it have any credit ratings from major rating agencies. The company has focused on equity financing, including a recent private placement in July 2023 that raised $30 million. Additionally, in April 2024, the company recognized $10 million from milestone payments under collaboration agreements.
Balancing Debt Financing and Equity Funding
CytomX balances its financing primarily through equity, reflecting its strategy to minimize financial risk while pursuing growth through partnerships and collaborations. The total stockholders' deficit as of September 30, 2024, was $23.5 million, down from $47.4 million at the end of 2023. This indicates an improvement in equity position driven by operational milestones and revenue growth from collaborations, which totaled $100 million for the nine months ended September 30, 2024.
| Financial Metric | As of September 30, 2024 | As of December 31, 2023 |
|---|---|---|
| Total Liabilities | $162.4 million | $249.2 million |
| Current Liabilities | $119.2 million | $155.9 million |
| Long-term Debt | $0 | $0 |
| Debt-to-Equity Ratio | 0 | N/A |
| Total Stockholders' Deficit | $23.5 million | $47.4 million |
| Total Revenue (9 months ended) | $100 million | $74.6 million |
Assessing CytomX Therapeutics, Inc. (CTMX) Liquidity
Assessing CytomX Therapeutics, Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current assets totaled $117.6 million with current liabilities of $26.4 million, resulting in a current ratio of approximately 4.45.
Quick Ratio: With cash and cash equivalents of $41.6 million, accounts receivable of $2.0 million, and no inventory, the quick ratio is also 4.45.
Analysis of Working Capital Trends
Working capital as of September 30, 2024, is calculated as current assets minus current liabilities. This results in working capital of $91.2 million.
Cash Flow Statements Overview
During the nine months ended September 30, 2024, the cash flow statement indicates:
| Type of Cash Flow | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(66,323) | $(34,072) |
| Net Cash Provided by Investing Activities | $84,565 | $(163,540) |
| Net Cash Provided by Financing Activities | $5,273 | $29,986 |
| Net Increase in Cash | $23,515 | $(167,626) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash, cash equivalents, and short-term investments totaled $117.6 million, while the accumulated deficit stood at $710.5 million. The company has sufficient liquidity to cover its current liabilities and fund operations through the end of 2025, provided that anticipated operating results and future financing are achieved.
Is CytomX Therapeutics, Inc. (CTMX) Overvalued or Undervalued?
Valuation Analysis
To assess the financial health of the company, various valuation metrics including price-to-earnings (P/E), price-to-book (P/B), and enterprise value-to-EBITDA (EV/EBITDA) ratios are crucial.
Valuation Ratios
- Price-to-Earnings (P/E) Ratio: As of September 30, 2024, the P/E ratio is 30.7, calculated using a net income of $5.736 million and a market capitalization of approximately $175 million.
- Price-to-Book (P/B) Ratio: The P/B ratio stands at 2.5, derived from total stockholders' equity of -$23.452 million and a market capitalization of $175 million.
- Enterprise Value-to-EBITDA (EV/EBITDA) Ratio: The EV/EBITDA ratio is 24.3, calculated using an enterprise value of approximately $175 million and EBITDA of $7.316 million.
Stock Price Trends
The stock price over the last 12 months has shown significant fluctuations:
| Date | Price ($) |
|---|---|
| September 2023 | 1.75 |
| December 2023 | 2.10 |
| March 2024 | 2.50 |
| June 2024 | 2.30 |
| September 2024 | 2.20 |
Dividend Yield and Payout Ratios
Currently, the company does not offer dividends, resulting in a dividend yield of 0%. The payout ratio is also 0% as there are no earnings distributed as dividends.
Analyst Consensus on Stock Valuation
Analysts have a mixed outlook on the stock valuation:
- Buy: 2 analysts
- Hold: 3 analysts
- Sell: 1 analyst
The consensus rating is currently Hold, reflecting cautious optimism about future performance based on recent operational developments.
Key Risks Facing CytomX Therapeutics, Inc. (CTMX)
Key Risks Facing CytomX Therapeutics, Inc.
The financial health of CytomX Therapeutics, Inc. is influenced by various internal and external risk factors that can significantly impact its operations and market position.
Overview of Internal and External Risks
As a clinical-stage biopharmaceutical company, CytomX faces numerous risks, including:
- Limited Operating History: The company has not generated any revenue from product sales and has a history of operating losses.
- Funding Requirements: Significant additional funds will be needed to advance product candidates, with no guarantee that such funding will be available on acceptable terms.
- Regulatory Challenges: The lengthy and expensive clinical development process is fraught with uncertainty. Results from earlier studies may not predict future outcomes.
- Competition: Intense competition from other biopharmaceutical companies could hinder the development and commercialization of product candidates.
- Market Conditions: Adverse financial market conditions can impact the company's ability to raise capital.
Operational, Financial, and Strategic Risks
Recent earnings reports highlight several risks that could impact CytomX's financial health:
- Clinical Development Risks: The company may face delays in clinical trials due to patient enrollment challenges, which could delay regulatory approvals.
- Manufacturing Dependencies: Reliance on third-party manufacturers for product candidates poses risks related to quality and supply.
- Stock Price Volatility: Fluctuations in stock price may affect the company's ability to raise funds through equity offerings.
- Legal and Compliance Risks: Potential legal proceedings and compliance with regulations such as the Sarbanes-Oxley Act may impact operations.
Mitigation Strategies
The company has outlined several strategies to mitigate risks, including:
- Raising Capital: Pursuing additional collaborations and equity offerings to secure funding.
- Research and Development Focus: Continuing to develop its PROBODY platform to generate innovative therapeutics.
- Monitoring Market Conditions: Keeping a close eye on financial market conditions to time funding efforts effectively.
Financial Data Overview
| Financial Metric | September 30, 2024 | December 31, 2023 |
|---|---|---|
| Cash and Cash Equivalents | $40.6 million | $17.2 million |
| Short-term Investments | $77.0 million | $157.3 million |
| Accumulated Deficit | $710.5 million | $723.4 million |
| Total Liabilities | $162.4 million | $249.2 million |
| Net Loss (Nine Months Ended) | $12.99 million | ($1.41 million) |
These key risks and financial metrics provide insight into the challenges and operational landscape facing CytomX Therapeutics, Inc. as of 2024.
Future Growth Prospects for CytomX Therapeutics, Inc. (CTMX)
Future Growth Prospects for CytomX Therapeutics, Inc.
Analysis of Key Growth Drivers
Key growth drivers for the company include:
- Product Innovations: The ongoing development of investigational bispecific cancer therapies utilizing the PROBODY therapeutic platform.
- Market Expansions: Collaborations with major pharmaceutical companies such as Regeneron and Moderna to enhance product pipelines.
- Acquisitions: Strategic partnerships that allow for shared resources and expertise in drug development.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the total revenue was $100.0 million, an increase of $25.4 million compared to the same period in 2023. The revenue growth was primarily attributed to:
- Increased revenue from the Bristol Myers Squibb Agreement, amounting to $56.0 million.
- Milestone payments from Astellas totaling $10.0 million for clinical candidates.
Strategic Initiatives or Partnerships Driving Future Growth
Strategic partnerships include:
- Collaboration with Regeneron: This partnership includes a $30.0 million upfront fee and potential milestone payments up to $0.8 billion.
- Collaboration with Moderna: Involves up to $1.2 billion in milestone payments and tiered royalties from sales.
Competitive Advantages Positioning for Growth
The company holds several competitive advantages:
- Innovative Technology: The proprietary PROBODY platform allows targeted therapy development.
- Strong Partnerships: Collaborations with industry giants enhance credibility and resource access.
- Robust Pipeline: Over 15 active drug discovery and development programs in progress.
Financial Overview
As of September 30, 2024, the financial position includes:
| Financial Metric | Value (in thousands) |
|---|---|
| Cash and Cash Equivalents | $40,576 |
| Short-term Investments | $77,012 |
| Accumulated Deficit | ($710,455) |
| Total Revenue (2024) | $100,010 |
Research and Development Investments
Research and development expenses for the nine months ended September 30, 2024, were:
| Expense Category | Value (in thousands) |
|---|---|
| Research and Development | $68,592 |
| General and Administrative | $24,102 |
| Total Operating Expenses | $92,694 |
CytomX Therapeutics, Inc. (CTMX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- CytomX Therapeutics, Inc. (CTMX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of CytomX Therapeutics, Inc. (CTMX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View CytomX Therapeutics, Inc. (CTMX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.